Alcobra Ltd. (ADHD) Stock Price Up 3.2%
Alcobra Ltd. (NASDAQ:ADHD) shares rose 3.2% during mid-day trading on Monday . The stock traded as high as $5.21 and last traded at $5.17, with a volume of 58,884 shares. The stock had previously closed at $5.01.
ADHD has been the subject of several recent analyst reports. Barclays PLC initiated coverage on Alcobra in a research note on Monday, August 1st. They set an “equal weight” rating and a $8.00 price objective for the company. Zacks Investment Research lowered Alcobra from a “hold” rating to a “sell” rating in a research note on Monday, July 18th. Canaccord Genuity assumed coverage on Alcobra in a research note on Tuesday, June 7th. They set a “buy” rating for the company. Jefferies Group restated a “buy” rating on shares of Alcobra in a research note on Thursday. Finally, Roth Capital restated a “buy” rating and issued a $12.00 target price on shares of Alcobra in a research note on Tuesday, June 21st. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $11.13.
The firm’s market capitalization is $145.80 million. The firm’s 50 day moving average price is $4.66 and its 200 day moving average price is $4.55.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.